Lupin & Zentiva Partner on Biosimilar

  Published 9 months ago

Lupin and Zentiva partner to commercialize biosimilar Certolizumab Pegol globally, sharing profits and development responsibilities.

  • Lupin handles development, manufacturing, and US/Canada commercialization; Zentiva leads efforts in Europe and CIS markets.
  • The agreement includes $10 million upfront and up to $50 million in milestone payments for Lupin.
  • Partnership targets global access to affordable, high-quality biosimilar therapy for autoimmune diseases.

You might like these

Honeywell to Acquire Johnson Matthey Catalyst Tech

TFCI to Propose Share Split in Upcoming Board Meeting

India's Manufacturing Sales Surge in 2024-25

Hindalco Acquires AluChem to Boost Specialty Alumina Growth

China's May Economy: Retail Rises, Tariffs Weigh

Aimtron's Transformer-Free UPS Innovation

India Sep Power Generation Slows

News that matters the most ⚡